Updates are available Correction dated 2022-12-19
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s40246-022-00443-7
-
Authors
Lee, Ning Yuan
Hum, Melissa
Amali, Aseervatham Anusha
Lim, Wei Kiat
Wong, Matthew
Myint, Matthew Khine
Tay, Ru Jin
Ong, Pei-Yi
Samol, Jens
Lim, Chia Wei
Ang, Peter
Tan, Min-Han
Lee, Soo-Chin
Lee, Ann S. G.
-
Funding
Funding for this research was provided by:
Agency for Science, Technology and Research (IAF-ICP: I1801E0021, IAF-ICP: I1801E0021, IAF-ICP: I1801E0021, IAF-ICP: I1801E0021)
- License Information
-
More Information
Article History
Received: 15 August 2022
Accepted: 14 November 2022
First Online: 23 November 2022
Change Date: 19 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s40246-022-00443-7
Declarations
:
: Written informed consent was obtained from all participants and the study was approved by the SingHealth Centralised Institutional Review Board (CIRB Ref: 2018/2147).
: Not applicable.
: P.A. reports receiving travel support and/or honoraria from AstraZeneca, DKSH, Eisai, Bristol Myers Squibb, Lilly, Novartis, Pfizer, Roche, and MSD, all of which are outside the submitted work. M.-H.T. reports being a director, shareholder, and Chief Executive Officer of Lucence, outside of the submitted work. S.-C.L. reports grant support/research collaborations with Pfizer, Eisai, Taiho, ACT Genomics, Bayer, and MSD; advisory board/speaker invitations from Pfizer, Novartis, Astra Zeneca, ACT Genomics, Eli Lilly, MSD, Roche, Eisai and Daiichi-Sankyo; conference support from Amgen, Pfizer and Roche, all of which are outside the submitted work. All other authors declare that they have no competing interests.
